A novel approach for the simultaneous quantification of a therapeutic monoclonal antibody in serum produced from two distinct host cell lines

mAbs

Volumn 5, Issue 1, 2013, Pages 150-161

  Geist, Brian J ^a   Davis, Darryl ^a   McIntosh, Thomas ^a   Yang, Tong Yuan ^a   Goldberg, Kenneth ^a   Han, Chao ^a   Pendley, Charles ^a   Davis, Hugh M ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Biocomparability; Bioequivalence; CHO and Sp2 0 cell lines; Glycosylation; Immunoaffinity purification; Immunoassay; LC MS; Liquid chromatography; Mass spectrometry; Therapeutic monoclonal antibody

Indexed keywords

SILTUXIMAB;

ACCURACY; ANIMAL CELL; ANTIBODY AFFINITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; GLYCOSYLATION; HOST CELL; IMMUNOAFFINITY PURIFICATION; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PURIFICATION; REPRODUCIBILITY;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; CHO CELLS; CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, LIQUID; CRICETINAE; GLYCOSYLATION; IMMUNOASSAY; MASS SPECTROMETRY; MICE; OLIGOSACCHARIDES;

EID: 84872855923     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.22773     Document Type: Article

References (44)

1. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 2011; 3:76-99; PMID:21051951; http://dx.doi.org/10.4161/mabs.3.1.13895
2. Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012; 4:413-5; PMID:22531442; http://dx.doi.org/10.4161/mabs.19931
3. DeSilva B, Smith W, Weiner R., Kelley M, Smolec J, Lee B., et al Recommendations for the bioanalytical method validation of ligand-binding assays to support phar-macokinetic assessments of macromolecules. Pharm Res 2003; 20:1885-900; PMID:14661937; http://dx.doi.org/10.1023/B:PHAM.0000003390.51761.3d
4. Viswanathan CT, Bansal S, Booth B., DeStefano AJ, Rose MJ, Sailstad J, et al Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res 2007; 24:1962-73; PMID:17458684; http://dx.doi.org/10.1007/s11095-007-9291-7
5. Pendley C, Schantz A, Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 2003; 5:172-9; PMID:12772508
6. Shankar G, Devanarayan V, Amaravadi L., Barrett YC, Bowsher R, Finco-Kent D, et al Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 2008; 48:1267-81; PMID:18993008; http://dx.doi.org/10.1016/j.jpba.2008.09.020
7. Lee J.W., Kelley M, King L.E., Yang J., Salimi-Moosavi H, Tang MT, et al Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J 2011; 13:99-110; PMID:21240643; http://dx.doi.org/10.1208/s12248-011-9251-3
8. Nowatzke WL, Rogers K, Wells E., Bowsher RR, Ray C, Unger S. Unique challenges of providing bioanalytical support for biological therapeutic phar-macokinetic programs. Bioanalysis 2011; 3:509-21; PMID:21388264; http://dx.doi.org/10.4155/bio.11.2
9. Lee J.W., Kelley M. Quality assessment of bioana-lytical quantification of monoclonal antibody drugs. Ther Deliv 2011; 2:383-96; PMID:22834008; http://dx.doi.org/10.4155/tde.10.99
10. Kaltashov IA, Bobst CE, Abzalimov R.R., Wang G., Baykal B, Wang S. Advances and challenges in analytical characterization of biotechnology products: mass spectrometry-based approaches to study properties and behavior of protein therapeutics. Biotechnol Adv 2012; 30:210-22; PMID:21619926; http://dx.doi.org/10.1016/j.biotechadv.2011.05.006
11. Zhang Z, Pan H, Chen X. Mass spectrometry for structural characterization of therapeutic antibodies. Mass Spectrom Rev 2009; 28:147-76; PMID:18720354; http://dx.doi.org/10.1002/mas.20190
12. Staub A, Guillarme D, Schappler J., Veuthey JL, Rudaz S. Intact protein analysis in the biopharma-ceutical field. J Pharm Biomed Anal 2011; 55:810-22; PMID:21334842; http://dx.doi.org/10.1016/j.jpba.2011.01.031
13. Kozlowski S, Swann P. Current and future issues in the manufacturing and development of monoclonal antibodies. Adv Drug Deliv Rev 2006; 58:707-22; PMID:16828921; http://dx.doi.org/10.1016/j.addr.2006.05.002
14. Liu H, Gaza-Bulseco G, Faldu D., Chumsae C, Sun J. Heterogeneity of monoclonal antibodies. J Pharm Sci 2008; 97:2426-47; PMID:17828757; http://dx.doi.org/10.1002/jps.21180
15. Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 2005; 21:11-6; PMID:15903235; http://dx.doi.org/10.1021/ bp040016j
16. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009; 8:226-34; PMID:19247305; http://dx.doi.org/10.1038/nrd2804
17. Huhn C, Selman MH, Ruhaak L.R., Deelder AM, Wuhrer M. IgG glycosylation analysis. Proteomics 2009; 9:882-913; PMID:19212958; http://dx.doi.org/10.1002/ pmic.200800715
18. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20:471-8; PMID:18606225; http://dx.doi.org/10.1016/j.coi.2008.06.007
19. Suzuki E, Niwa R, Saji S., Muta M, Hirose M, Iida S., et al A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clin Cancer Res 2007; 13:1875-82; PMID:17363544; http://dx.doi.org/10.1158/1078-0432.CCR-06-1335
20. Keck R, Nayak N, Lerner L., Raju S, Ma S, Schreitmueller T., et al Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content. Biologicals 2008; 36:49-60; PMID:17728143; http://dx.doi.org/10.1016/j.biologicals.2007.05.004
21. Millward TA, Heitzmann M, Bill K., Längle U, Schumacher P., Forrer K. Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice. Biologicals 2008; 36:41-7; PMID:17890101; http://dx.doi.org/10.1016/j.biologicals.2007.05.003
22. Scallon BJ, Tam SH, McCarthy S.G., Cai AN, Raju TS Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 2007; 44:1524-34; PMID:17045339; http://dx.doi.org/ 10.1016/j.molimm.2006.09.005
23. Sundaram S, Matathia A, Qian J., Zhang J, Hsieh MC, Liu T, et al An innovative approach for the characterization of the isoforms of a monoclonal antibody product. MAbs 2011; 3:505-12; PMID:22123057; http://dx.doi.org/10.4161/ mabs.3.6.18090
24. Xie H, Chakraborty A, Ahn J., Yu YQ, Dakshinamoorthy D P, Gilar M, et al Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. MAbs 2010; 2:1-16; PMID:20065628
25. Damen CW, Chen W, Chakraborty A.B., van Oosterhout M, Mazzeo JR, Gebler J.C., et al Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab. J Am Soc Mass Spectrom 2009; 20:2021-33; PMID:19744865; http://dx.doi.org/10.1016/j. jasms.2009.07.017
26. Zamani L, Lindholm J, Ilag L.L., Jacobsson S P. Discrimination among IgG1-kappa monoclonal antibodies produced by two cell lines using charge state distributions in nanoESI-TOF mass spectra. J Am Soc Mass Spectrom 2009; 20:1030-6; PMID:19251439; http://dx.doi.org/10.1016/j.jasms.2009.01.008
27. Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 2004; 22:1383-91; PMID:15529163; http://dx.doi.org/10.1038/nbt1030
28. Goetze AM, Schenauer MR, Flynn GC Assessing monoclonal antibody product quality attribute criticality through clinical studies. MAbs 2010; 2:500-7; PMID:20671426; http://dx.doi.org/10.4161/mabs.2.5.12897
29. Schiestl M, Stangler T, Torella C., Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29:310-2; PMID:21478841; http://dx.doi.org/10.1038/nbt.1839
30. US Food and Drug Administration. Guidance for Industry: Q5E Comparability of Biotechnological/ Biological Products Subject to Changes in their Manufacturing Process, 2005. http://www.fda.gov/downloads/RegulatoryInformation/ Guidances/ucm128076.pdf
31. US Food and Drug Administration. Guidance for Industry: Q6B Specifications: Test Procedures And Acceptance Criteria For Biotechnological / Biological Products, 1999. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm073488.pdf
32. Lee JW, Wang YM, Moxness M, DeSilva B. Bioanalytical considerations in the comparability assessment of biotherapeutics. Bioanalysis 2011; 3:613-22; PMID:21417731; http://dx.doi.org/10.4155/bio.11.25
33. Dirks NL, Meibohm B. Population pharmacoki-netics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49:633-59; PMID:20818831; http://dx.doi.org/10.2165/11535960-000000000-00000
34. Mauko L, Nordborg A, Hutchinson J P, Lacher NA, Hilder E F, Haddad PR Glycan profiling of monoclonal antibodies using zwitterionic-type hydrophilic interaction chromatography coupled with electrospray ionization mass spectrometry detection. Anal Biochem 2011; 408:235-41; PMID:20887707; http://dx.doi.org/10.1016/j.ab.2010.09.035
35. Alvarez M, Tremintin G, Wang J., Eng M, Kao YH, Jeong J, et al On-line characterization of monoclonal antibody variants by liquid chromatography-mass spectrometry operating in a two-dimensional format. Anal Biochem 2011; 419:17-25; PMID:21867674; http://dx.doi.org/10.1016/j.ab.2011.07.033
36. Gilar M, Yu YQ, Ahn J, Xie H., Han H, Ying W, et al Characterization of glycoprotein digests with hydrophilic interaction chromatography and mass spectrometry. Anal Biochem 2011; 417:80-8; PMID:21689629; http://dx.doi.org/10. 1016/j.ab.2011.05.028
37. Yan B, Valliere-Douglass J, Brady L., Steen S, Han M, Pace D., et al Analysis of post-translational modifications in recombinant monoclonal antibody IgG1 by reversed-phase liquid chromatography/mass spectrometry. J Chromatogr A 2007; 1164:153-61; PMID:17640657; http://dx.doi.org/10.1016/j.chroma.2007.06.063
38. Dillon TM, Bondarenko PV, Rehder D.S., Pipes GD, Kleemann GR, Ricci MS Optimization of a reversed-phase high-performance liquid chromatography/mass spectrometry method for characterizing recombinant antibody heterogeneity and stability. J Chromatogr A 2006; 1120:112-20; PMID:16448656; http://dx.doi.org/ 10.1016/j.chroma.2006.01.016
39. Beck A, Bussat MC, Zorn N, Robillard V., Klinguer-Hamour C, Chenu S, et al Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 819:203-18; PMID:15833284; http://dx.doi.org/10.1016/j.jchromb.2004.06.052
40. Liu H, Manuilov AV, Chumsae C, Babineau M.L., Tarcsa E. Quantitation of a recombinant monoclonal antibody in monkey serum by liquid chromatography-mass spectrometry. Anal Biochem 2011; 414:147-53; PMID:21396346; http://dx.doi.org/ 10.1016/j.ab.2011.03.004
41. Cingöz A., Hugon-Chapuis F, Pichon V. Total on-line analysis of a target protein from plasma by immuno-extraction, digestion and liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878:213-21; PMID:19665945; http://dx.doi.org/10.1016/j.jchromb.2009.07.032
42. Murphy RE, Kinhikar AG, Shields M.J., Del Rosario J, Preston R, Levin N., et al Combined use of immu-noassay and two-dimensional liquid chromatography mass spectrometry for the detection and identification of metabolites from biotherapeutic pharmacoki-netic samples. J Pharm Biomed Anal 2010; 53:221-7; PMID:20547023; http://dx.doi.org/10.1016/j.jpba.2010.04.028
43. Damen C.W., Derissen EJ, Schellens J.H., Rosing H., Beijnen JH The bioanalysis of the monoclonal antibody trastuzumab by high-performance liquid chro-matography with fluorescence detection after immuno-affinity purification from human serum. J Pharm Biomed Anal 2009; 50:861-6; PMID:19487098; http://dx.doi.org/10.1016/j.jpba.2009.04.031
44. Dubois M, Fenaille F, Clement G., Lechmann M, Tabet JC, Ezan E, et al Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum. Anal Chem 2008; 80:1737-45; PMID:18225864; http://dx.doi.org/10.1021/ac7021234